Marten Visser

1.5k citations

15 papers · 1.1k indexed · 1 hit paper · h-index 10

Co-authors: Els M.E. Verdegaal Sjoerd H. van der Burg John B.A.G. Haanen Ton N. Schumacher Marit M. van Buuren Hergen Spits Remko Schotte Ellen Kapiteijn
Topics: Immunotherapy and Immune Responses (12 papers)CAR-T cell therapy research (11 papers)Cancer Immunotherapy and Biomarkers (9 papers)
Cited by: Immunology Oncology Cancer Research
Journals: Nature Nature MedicineSHILAP Revista de lepidopterología
Partner nations: Netherlands Denmark United Kingdom

In The Last Decade

Marten Visser

13 papers receiving 1.1k citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

High-throughput epitope discovery reveals frequent recognition of neo-antigens by CD4+ T cells in human melanoma

2014 527 citations Carsten Linnemann, Marit M. van Buuren et al. Nature Medicine profile →

Peers

Countries citing papers authored by Marten Visser

Since Specialization

Citations

This map shows the geographic impact of Marten Visser's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Marten Visser with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Marten Visser more than expected).

Fields of papers citing papers by Marten Visser

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Marten Visser. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Marten Visser. The network helps show where Marten Visser may publish in the future.

Co-authorship network of co-authors of Marten Visser

This figure shows the co-authorship network connecting the top 25 collaborators of Marten Visser. A scholar is included among the top collaborators of Marten Visser based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Marten Visser. Marten Visser is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

15 of 15 papers shown

#	Work	Indexed citations
1	Timed adoptive T cell transfer during chemotherapy in patients with recurrent platinum-sensitive epithelial ovarian cancer 2023 ·Journal for ImmunoTherapy of Cancer ·Els M.E. Verdegaal,Saskia J. Santegoets,Marij J.P. Welters,(unknown),Marten Visser,Caroline E. van der Minne,(unknown),Nikki M. Loof,(unknown),(unknown),Inge M. Westra,Pauline Meij,Sjoerd H. van der Burg,Judith R. Kroep	16
2	Tumor-Infiltrating T Cells Can Be Expanded Successfully from Primary Uveal Melanoma after Separation from Their Tumor Environment 2022 ·SHILAP Revista de lepidopterología ·Gülçin Gezgin,Marten Visser,Dina Ruano,Saskia J. Santegoets,Noel F.C.C. de Miranda,Pieter A. van der Velden,Gregorius P. M. Luyten,Sjoerd H. van der Burg,Els M.E. Verdegaal,Martine J. Jager	14
3	343 Identification of tumor-reactive T cells targeting melanoma Dark Antigens™ validates this novel class of targets for development of immunotherapies 2022 ·Regular and Young Investigator Award Abstracts ·Rachel Abbott,Tom Hofland,(unknown),(unknown),Michael J. Crowther,Joseph Dukes,Shawez Khan,(unknown),Giulia Masi,Özcan Met,(unknown),Hayden Selvadurai,Marten Visser,(unknown),Sjoerd van der Burg,George Kassiotis,Inge Marie Svane	0
4	729P Adoptive T-cell therapy during chemotherapy with or without peginterferon-α (IFNα) in patients with platinum sensitive recurrent epithelial ovarian cancer (EOC) 2021 ·Annals of Oncology ·Judith R. Kroep,Marten Visser,(unknown),(unknown),(unknown),Pauline Meij,Sjoerd van der Burg,(unknown)	1
5	Phase I/II study protocol to assess safety and efficacy of adoptive cell therapy with anti-PD-1 plus low-dose pegylated-interferon-alpha in patients with metastatic melanoma refractory to standard of care treatments: the ACTME trial 2020 ·BMJ Open ·Monique K. van der Kooij,Els M.E. Verdegaal,Marten Visser,(unknown),Caroline E. van der Minne,(unknown),(unknown),(unknown),(unknown),Gerrit‐Jan Liefers,Frank M. Speetjens,Sjoerd H. van der Burg,Ellen Kapiteijn	8
6	Simplified Monopalmitoyl Toll‐like Receptor 2 Ligand Mini‐UPam for Self‐Adjuvanting Neoantigen‐Based Synthetic Cancer Vaccines 2020 ·ChemBioChem ·(unknown),(unknown),(unknown),Marten Visser,(unknown),Nataschja I. Ho,Wim Jiskoot,A. Rob P.M. Valentijn,Nico J. Meeuwenoord,Herman S. Overkleeft,Jeroen D. C. Codée,Sjoerd H. van der Burg,Els M.E. Verdegaal,Gijsbert A. van der Marel,Ferry Ossendorp,Dmitri V. Filippov	5
7	Low-dose interferon-alpha preconditioning and adoptive cell therapy in patients with metastatic melanoma refractory to standard (immune) therapies: a phase I/II study 2020 ·Journal for ImmunoTherapy of Cancer ·Els M.E. Verdegaal,Monique K. van der Kooij,Marten Visser,(unknown),(unknown),Pauline Meij,(unknown),Marij J.P. Welters,Saskia J. Santegoets,Noel F.C.C. de Miranda,(unknown),Gerrit‐Jan Liefers,Ellen Kapiteijn,Sjoerd H. van der Burg	19
8	Neoantigen-specific immunity in low mutation burden colorectal cancers of the consensus molecular subtype 4 2019 ·Genome Medicine ·Jitske van den Bulk,Els M.E. Verdegaal,Dina Ruano,Marieke E. Ijsselsteijn,Marten Visser,Ruud van der Breggen,Thomas Duhen,Manon van der Ploeg,N. de Vries,Jan Oosting,Koen Peeters,Andrew D. Weinberg,Arantza Fariña Sarasqueta,Sjoerd H. van der Burg,Noel F.C.C. de Miranda	47
9	Long-term Survival and Clinical Benefit from Adoptive T-cell Transfer in Stage IV Melanoma Patients Is Determined by a Four-Parameter Tumor Immune Signature 2017 ·Cancer Immunology Research ·Sara M. Melief,Valeria Visconti,Marten Visser,Merel van Diepen,Ellen Kapiteijn,Joost H. van den Berg,John B.A.G. Haanen,Vincent T.H.B.M. Smit,Jan Oosting,Sjoerd H. van der Burg,Els M.E. Verdegaal	24
10	IDO and galectin-3 hamper the ex vivo generation of clinical grade tumor-specific T cells for adoptive cell therapy in metastatic melanoma 2017 ·Cancer Immunology Immunotherapy ·Sara M. Melief,Marten Visser,Sjoerd H. van der Burg,Els M.E. Verdegaal	16
11	Neoantigen landscape dynamics during human melanoma–T cell interactions 2016 ·Nature ·Els M.E. Verdegaal,Noel F.C.C. de Miranda,Marten Visser,Tom J. Harryvan,Marit M. van Buuren,Rikke Andersen,Sine Reker Hadrup,Caroline E. van der Minne,Remko Schotte,Hergen Spits,John B.A.G. Haanen,Ellen Kapiteijn,Ton N. Schumacher,Sjoerd H. van der Burg	339
12	High-throughput epitope discovery reveals frequent recognition of neo-antigens by CD4(+) T cells in human melanoma (vol 21, pg 81, 2015) 2016 ·Pure Amsterdam UMC ·Carsten Linnemann,Marit M. van Buuren,Laura Bies,Els M.E. Verdegaal,Remko Schotte,Jorg J. A. Calis,Sam Behjati,Arno Velds,Henk Hilkmann,Dris El Atmioui,Marten Visser,Michael R. Stratton,John B.A.G. Haanen,Hergen Spits,Sjoerd H. van der Burg,Ton N. Schumacher	0
13	High-throughput epitope discovery reveals frequent recognition of neo-antigens by CD4+ T cells in human melanomabreakdown → 2014 ·Nature Medicine ·Carsten Linnemann,Marit M. van Buuren,Laura Bies,Els M.E. Verdegaal,Remko Schotte,Jorg J. A. Calis,Sam Behjati,Arno Velds,Henk Hilkmann,Dris El Atmioui,Marten Visser,Michael R. Stratton,John B.A.G. Haanen,Hergen Spits,Sjoerd H. van der Burg,Ton N. Schumacher	527
14	Inhibition of the type I immune responses of human monocytes by IFN-α and IFN-β 2013 ·Cytokine ·Roelof A. de Paus,Annelies van Wengen,Iris Schmidt,Marten Visser,Els M.E. Verdegaal,Jaap T. van Dissel,Esther van de Vosse	48
15	Successful treatment of metastatic melanoma by adoptive transfer of blood-derived polyclonal tumor-specific CD4+ and CD8+ T cells in combination with low-dose interferon-alpha 2011 ·Cancer Immunology Immunotherapy ·Els M.E. Verdegaal,Marten Visser,Tamara H. Ramwadhdoebé,Caroline E. van der Minne,(unknown),Ellen Kapiteijn,John B.A.G. Haanen,Sjoerd H. van der Burg,J.W.R. Nortier,Susanne Osanto	57

About Marten Visser

Marten Visser is a scholar working on Immunology, Oncology and Ophthalmology, having authored 15 papers that have together received 1.1k indexed citations. Recurring topics across this work include Immunotherapy and Immune Responses (12 papers), CAR-T cell therapy research (11 papers) and Cancer Immunotherapy and Biomarkers (9 papers). The work is most often cited by research in Immunology (867 citations), Oncology (869 citations) and Cancer Research (69 citations). Marten Visser has collaborated with scholars based in Netherlands, Denmark and United Kingdom. Frequent co-authors include Els M.E. Verdegaal, Sjoerd H. van der Burg, John B.A.G. Haanen, Ton N. Schumacher, Marit M. van Buuren, Hergen Spits, Remko Schotte, Ellen Kapiteijn, Dris El Atmioui and Michael R. Stratton. Their work appears in journals such as Nature, Nature Medicine and SHILAP Revista de lepidopterología.

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact